<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[therapy Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/therapy.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to therapy]]></description>
	<s:counts start="0" returned="20" found="1371" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Occupational Therapist, Registered]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=322777]]></link>
		<description><![CDATA[The Occupational Therapist, Registered job description template includes the following job summary: To provide, under the general supervision of the occupational therapy director and according to established policies and procedures of the department, diagnostic evaluations and treatment to assigned patients, to help patients reach maximum performance level, and to use...]]></description>
		<s:doctype><![CDATA[Tools & templates]]></s:doctype>
		<pubDate>Sun, 01 Nov 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/business+%2526+legal+reports+inc..html"><![CDATA[Business & Legal Reports Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
	</item>
	<item>
		<title><![CDATA[Biogen-Idec's Tysabri Problems May Be Fault of European Doctors]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005010/biogen-idecs-tysabri-problems-may-be-fault-of-european-doctors/]]></link>
		<description><![CDATA[As mentioned in my last BNET Pharma posting, Biogen Idec's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML -- with most confirmed cases centered in Europe, in particular Germany. Could there be a link...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 27 Oct 2009 09:47:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/germany.html"><![CDATA[Germany]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/biogen-idec.html"><![CDATA[Biogen-Idec]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/pml.html"><![CDATA[PML]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="tickers">BIIB,MSFT</category>
	</item>
	<item>
		<title><![CDATA[Whatever Tysabri Outcome, Biogen Idec Should Survive]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005002/whatever-tysabri-outcome-biogen-idec-should-survive/]]></link>
		<description><![CDATA[Biogen Idec's key multiple sclerosis drug is in the news again, as the European Medicines Agency EMEA has started a safety review of Tysabri, citing more confirmed cases of a rare -- but potentially fatal -- viral infection of the brain, called progressive multifocal leukoencephalopathy PML, previously linked to the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 26 Oct 2009 11:21:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/progressive+multifocal+leukoencephalopathy.html"><![CDATA[Progressive Multifocal Leukoencephalopathy]]></category>
		<category domain="http://resources.bnet.com/topic/avonex.html"><![CDATA[Avonex]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Celgene Corporation Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-355423.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions And we will take our first question from Maged Shenouda with UBS. Maged Shenouda &#8211; UBS Hi. Thanks for taking my question. Can you outline your plans for top line growth over the next few years as we wait for execution on your...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 22 Oct 2009 11:43:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/japan.html"><![CDATA[Japan]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Amylin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-354547.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions Your first question comes from Cory Kasimov from J.P. Morgan. Mona Nilsson - J.P. Morgan This is actually Mona for Cory.  My first question is actually on the 120-day safety update.  I was wondering if you are in a position to share...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 16:37:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/analysis.html"><![CDATA[Analysis]]></category>
		<category domain="http://resources.bnet.com/topic/amylin+pharmaceuticals+inc..html"><![CDATA[Amylin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMLN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="tickers">AMLN,JPM</category>
	</item>
	<item>
		<title><![CDATA[GDP: Out, Joie de Vivre: In]]></title>
		<link><![CDATA[http://moneywatch.bnet.com/economic-news/blog/financial-decoder/gdp-out-joie-de-vivre-in/704/]]></link>
		<description><![CDATA[I've been so wrapped up in the preparation for the one-year anniversary of the financial melt-down,Â  that I've blown off working out, physical therapy appointments and my friends . This is not a great revelation--we're all working harder than ever, which is why I was drawn to a story this...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 18 Sep 2009 06:41:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/gross+domestic+product.html"><![CDATA[Gross Domestic Product]]></category>
		<category domain="http://resources.bnet.com/topic/president.html"><![CDATA[President]]></category>
		<category domain="http://resources.bnet.com/topic/nicolas+sarkozy.html"><![CDATA[Nicolas Sarkozy]]></category>
		<category domain="http://resources.bnet.com/topic/income.html"><![CDATA[Income]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/personal+finance.html"><![CDATA[Personal Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jill+schlesinger.html"><![CDATA[Jill Schlesinger]]></category>
	</item>
	<item>
		<title><![CDATA[Online Therapy: Help 4 Nuts?]]></title>
		<link><![CDATA[http://blogs.bnet.com/ceo/?p=2877]]></link>
		<description><![CDATA[No, The Corner Office hasn't gone mental. But it's fascinated by a TechCrunch50 entrepreneur with a unique business plan that targets 57 million Americans with a diagnosed mental illness. But is BreakThrough's telepsychiatry just feeding America's growing appetite for quick fixes?      And this is further...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 17 Sep 2009 14:10:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/appetite.html"><![CDATA[Appetite]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/techcrunch50.html"><![CDATA[TechCrunch50]]></category>
		<category domain="http://resources.bnet.com/topic/entrepreneurship.html"><![CDATA[Entrepreneurship]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/steve+tobak.html"><![CDATA[Steve Tobak]]></category>
	</item>
	<item>
		<title><![CDATA[United Therapeutics Corp. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-327173.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Instructions Operator Instructions Our first question comes from Salveen Kochnover &#8211; Collins Stewart Llc. Salveen Kochnover &#8211; Collins Stewart Llc  Could you provide us with any color on Tyvaso pricing and just comment on the sales force positioning of Adcirca and Tyvaso to physicians. ...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 11:26:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/pricing+strategy.html"><![CDATA[Pricing Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/united+therapeutics+corp..html"><![CDATA[United Therapeutics Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/tyvaso.html"><![CDATA[Tyvaso]]></category>
		<category domain="http://resources.bnet.com/topic/remodulin.html"><![CDATA[Remodulin]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UTHR</category>
		<category domain="tickers">UTHR</category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly and Company Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-323501.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from the line of John Boris from Citi. Please go ahead. John Boris &#8211; Citi Thanks for taking the questions. First question just has to do with the EPS increase of about $0.05 on your guidance range. It seems...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 22 Jul 2009 10:57:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001372/forest-labs-lexapro-flap-over-jama-article-will-likely-be-examined-by-the-feds/]]></link>
		<description><![CDATA[An editor of the Journal of the American Medical Association called a university professor "a nobody and a nothing" after he pointed out, correctly, that a JAMA author had failed to disclose a financial relationship with Forest Labs in an article about Lexapro, according to the WSJ.   ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 16 Mar 2009 11:35:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/superior.html"><![CDATA[Superior]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/jama.html"><![CDATA[JAMA]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[U.S. Physical Therapy 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-276202.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operators Instructions. Your first question comes from the line of Larry Solow of CJS Securities. Christopher Reading Hi, Larry. Lawrence Solow - CJS Securities Hi, guys, how is it going. Just a question, first of all on the Q4 would it be fair to say that visits...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 05 Mar 2009 11:14:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+physical+therapy+inc..html"><![CDATA[U.S. Physical Therapy Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">USPH</category>
		<category domain="tickers">USPH</category>
	</item>
	<item>
		<title><![CDATA[Savient Pharmaceuticals, Inc, Q4 Year Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-273364.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions  And we'll go first to Eric Varma with Leerwink Swann.  Eric Varma &#8211; Leerwink Swann Hey, good morning I had a quick question on a follow-on about febuxostat.  If you can just kind of remind us how the CV incidents compare between...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 26 Feb 2009 12:31:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/savient+pharmaceuticals+inc..html"><![CDATA[Savient Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SVNT</category>
		<category domain="tickers">SVNT</category>
	</item>
	<item>
		<title><![CDATA[Kinetic Concepts, Inc., Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-264357.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions.  Your first question comes from the line of Michael Matson from Wachovia Capital Markets. Michael Matson - Wachovia Capital Markets I was wondering if you could give us a little more detail on the commentary in the press release about the days of use...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 27 Jan 2009 11:02:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/kinetic+concepts+inc..html"><![CDATA[Kinetic Concepts Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KCI</category>
		<category domain="tickers">KCI</category>
	</item>
	<item>
		<title><![CDATA[The ROI For Targeted Therapies: A Strategic Perspective Assessing The Barriers And Incentives]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=932605]]></link>
		<description><![CDATA[Personalized medicine has the power to transform health care within the foreseeable future, from a populationbased model to a subpopulation and individual model. Scientific advances in biotechnology, Health Information Technology HIT, genomics, proteomics, therapeutic delivery, and computational biology have made possible a new approach to the diagnosis, treatment, and management...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 27 Jan 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/barrier.html"><![CDATA[Barrier]]></category>
		<category domain="http://resources.bnet.com/topic/incentive.html"><![CDATA[Incentive]]></category>
		<category domain="http://resources.bnet.com/topic/roi.html"><![CDATA[ROI]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
	</item>
	<item>
		<title><![CDATA[Occupational Therapy Assistant Resume Cover Letter]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1106471]]></link>
		<description><![CDATA[This is a template for occupational therapy assistant resume cover letter. If you are applying for a occupational therapy assistant job, don't forget to send such cover letter with it. ]]></description>
		<s:doctype><![CDATA[Tools & templates]]></s:doctype>
		<pubDate>Thu, 01 Jan 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
	</item>
	<item>
		<title><![CDATA[Sample Respiratory Therapist Technician Cover Letter]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1129415]]></link>
		<description><![CDATA[Use this template as a cover letter to apply for the post of respiratory therapy technician. A respiratory therapy technician cover letter can be just the document you need to catch the attention of the hiring manager at a hospital - especially if you include what is most important -...]]></description>
		<s:doctype><![CDATA[Tools & templates]]></s:doctype>
		<pubDate>Thu, 01 Jan 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/job+bank+usa.html"><![CDATA[Job Bank USA]]></category>
		<category domain="http://resources.bnet.com/topic/therapy+technician.html"><![CDATA[Therapy Technician]]></category>
	</item>
	<item>
		<title><![CDATA[Managed Care And Contracting Strategy For The Life Sciences Industry]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=932419]]></link>
		<description><![CDATA[The life sciences industry has long been considered dynamic and evolutionary in terms of the science underpinning its innovative therapies. Now, the same can be said of the market forces that influence the uptake of those therapies. With health care cost containment pressures continuing to grow alongside intensifying competition, the...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 06 Nov 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/deloitte+touche+tohmatsu.html"><![CDATA[Deloitte Touche Tohmatsu]]></category>
		<category domain="http://resources.bnet.com/topic/life+sciences+industry.html"><![CDATA[Life Sciences Industry]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
	</item>
	<item>
		<title><![CDATA[RehabCare Group, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-244944.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you.  We will now begin the question and answer session.  Operator Instructions.  Our first question comes from Kemp Dolliver from Cowen and Company, please go ahead.   Kemp Dolliver - Cowen and Company John, after that closing, I&#8217;ve decided that CNN needs...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 29 Oct 2008 15:23:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/rehabcare+group+inc..html"><![CDATA[RehabCare Group Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/accrual.html"><![CDATA[Accrual]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/rehabcare+group+inc..html"><![CDATA[RehabCare Group Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/accrual.html"><![CDATA[Accrual]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RHB</category>
		<category domain="tickers">RHB</category>
	</item>
	<item>
		<title><![CDATA[TomoTherapy to Present at Oppenheimer Healthcare Conference]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_27/ai_n30937820]]></link>
		<description><![CDATA[MADSION, Wis. -- TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Dr. Fred Robertson, CEO, and Steve Hathaway, CFO, will present at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 p.m., ET. The conference is scheduled for November 3-4 at the Waldorf-Astoria Hotel in New York...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/conference.html"><![CDATA[conference]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent From the U.S. Patent Office for Novel Obesity Therapy]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200810/ai_n30945113]]></link>
		<description><![CDATA[Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,138,107) by the U.S. Patent and Trademark Office USPTO for its invention entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders."...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent and Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
